Table 5.
Frequencies of the individual complications mentioned, per cohort, for the 40 overlapping donors. Percentages between brackets.
| Cohort A | Cohort B | p-Value | |
|---|---|---|---|
| Short-term complications | |||
| Fatigue | 18 (45) | 22 (55) | 0.42 |
| Infection (NOS) | 12 (30) | 10 (25) | 0.79 |
| Pain | 12 (30) | 11 (27.5) | 1 |
| Wound infection | 8 (20) | 15 (37.5) | 0.09 |
| Thrombosis | 6 (15) | 10 (25) | 0.22 |
| Bleeding | 6 (15) | 16 (40) | 0.006 |
| Death | 5 (12.5) | 6 (15) | 1 |
| Pneumonia | 5 (12.5) | 7 (17.5) | 0.69 |
| Urinary tract infection | 3 (7.5) | 9 (22.5) | 0.07 |
| Cardiovascular complications | 0 | 1 (2.5) | 1 |
| Neuropathy/neurapraxia | 0 | 3 (7.5) | 0.25 |
| Long-term complications | |||
| ESKD | 6 (15) | 11 (27.5) | 0.23 |
| Medication (NSAIDs, AB) | 1 (2.5) | 0 | 1 |
| Chronic pain | 1 (2.5) | 1 (2.5) | 1 |
| Hypertension | 0 | 3 (7.5) | 0.25 |
NOS: not otherwise specified; ESKD: end-stage kidney disease.